1、Vertex Reports Third Quarter 2025 Financial ResultsNovember 3,2025 Total revenue of$3.08 billion,an 11%increase compared to Q3 2024 Refined full year financial guidance:total revenue guidance now$11.9 to$12.0 billion and total combined non-GAAP R&D,AIPR&D,and SG&Aexpense guidance now$5.0 to$5.1 bill

2、ion R&D pipeline continues to make progress:five programs in pivotal development and povetacicept Phase 3 IgAN trial full enrollment complete;ontrack to submit first module of povetacicept IgAN BLA to FDA by end of 2025 BOSTON-(BUSINESS WIRE)-Nov.3,2025-Vertex Pharmaceuticals Incorporated(Nasdaq:VRT

3、X)today reported consolidated financial results forthe third quarter ended September 30,2025,and refined full year 2025 financial guidance.“Vertex delivered strong results across the board in the third quarter,extending our leadership in CF,continuing to build global momentum forCASGEVY,and advancin

4、g the launch of JOURNAVX in acute pain,”said Reshma Kewalramani,M.D.,Chief Executive Officer and President of Vertex.“We also delivered strong progress across the R&D pipeline,with completion of enrollment in the Phase 3 study of povetacicept in IgAN,initiation ofthe Phase 2/3 study of povetacicept

5、in primary membranous nephropathy,as well as advancement of several programs in research and earlier-stageclinical development.For the remainder of 2025,we are focused on executing the ongoing launches,initiating the povetacicept BLA submission inIgAN for potential U.S.accelerated approval,advancing

6、 the pipeline,and preparing for new launches in additional disease areas.”Third Quarter 2025 ResultsTotal revenue increased 11%to$3.08 billion compared to the third quarter of 2024,primarily driven by the continued performance of cystic fibrosis(CF)therapies and early contributions from the three on